Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Bristol-Myers Squibb and Allergan have formed an agreement to develop and commercialize Allergan’s AGN-209323, an oral drug in clinical development for neuropathic pain. Under the deal, Allergan grants BMS worldwide rights to the “Phase II ready” compound, except for use in products formulated for local delivery to the eye. BMS will pay Allergan $40 million up front and could owe the firm up to $373 million in milestone payments.
This article has been sent to the following recipient: